文献速递糖尿病

芬兰糖尿病预防研究中临床诊断视网膜病变的长期累积发病率

Long-term Cumulative Incidence of Clinically Diagnosed Retinopathy in the Finnish Diabetes Prevention Study.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

研究基于芬兰糖尿病预防研究(DPS)505例糖耐量受损者,原随机分为生活方式干预组(257例)与常规照护对照组(248例),中位随访22年。干预组与对照组临床诊断糖尿病视网膜病变累积发病率无显著差异(8.9% vs 7.7%,OR 1.15,95%CI 0.61-2.21);累积HbA1c较高与视网膜病变风险升高显著相关(HR 1.4,95%CI 1.02-1.88)。

要点

  • 中位随访22年,原生活方式干预组与对照组临床诊断视网膜病变累积发病率无显著差异(8.9% vs 7.7%)。
  • 累积HbA1c较高与视网膜病变风险升高显著相关(HR 1.4,95%CI 1.02-1.88)。
  • 随访期间发生糖尿病者视网膜病变诊断比例33/349,未发生者为9/156,比较未达统计学显著(OR 1.86,95%CI 0.89-4.28)。

核心结论

  • 较高的累积HbA1c与较高的视网膜病变风险显著相关。
  • 在中位22年随访期间,未发现4年生活方式干预对临床糖尿病视网膜病变长期发生产生有益作用的证据。

研究设计与样本

  • 研究纳入芬兰糖尿病预防研究(DPS)中505例糖耐量受损者,研究开始时平均年龄55岁(范围40-64岁)。
  • 受试者原随机分为生活方式干预组(减重、健康饮食和体力活动,N=257)与常规照护对照组(N=248)。
  • 中位随访时间为22年,临床视网膜病变诊断取自芬兰国家医院健康照护登记库。
  • 干预期间(中位4年)及干预后期间(直至第7年)的血糖参数、血脂和血压数据均可获得。

主要发现

  • 延长随访期间,原干预组(N=23,8.9%)与对照组(N=19,7.7%)临床诊断视网膜病变累积发病率无显著差异(OR 1.15,95%CI 0.61-2.21)。
  • 较高的累积HbA1c与较高的视网膜病变风险显著相关(HR 1.4,95%CI 1.02-1.88,95%后验区间,校正组别、年龄和性别)。
  • 随访期间发生糖尿病者视网膜病变诊断比例(33/349)在数值上高于未发生糖尿病者(9/156),但比较未达统计学显著(OR 1.86,95%CI 0.89-4.28,校正组别、年龄和性别)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Lifestyle intervention reduces the incidence of type 2 diabetes (T2D) in people with impaired glucose tolerance (IGT). OBJECTIVE: This work aimed to find out whether participation in an earlier lifestyle intervention had an effect on the occurrence of clinically diagnosed diabetic retinopathy (DR) during a median of 22 years of follow-up time. METHODS: The study included 505 individuals from the Finnish Diabetes Prevention Study (DPS) (mean age 55; range, 40-64 years at the onset of the study) with IGT who were originally randomly assigned to the intervention (weight loss, healthy diet, and physical activity) (N = 257) and usual care control groups (N = 248). The median follow-up was 22 years. Clinical retinopathy diagnoses were obtained from the Finnish national hospital Care Register for Health. Data on glycemic parameters, serum lipids, and blood pressure were available from both the intervention (median 4 years) and postintervention period (until year 7). RESULTS: No significant difference was found in the cumulative incidence of clinically diagnosed DR between the original intervention (N = 23, 8.9%) and control groups (N = 19, 7.7%) during the extended follow-up (odds ratio: 1.15; 95% CI, 0.61-2.21). A higher cumulative glycated hemoglobin A1c (HbA1c) was significantly associated with a higher risk of retinopathy (hazard ratio 1.4; 1.02-1.88, 95% posterior interval, adjusted for group, age, and sex). Furthermore, the incidence of retinopathy diagnosis was numerically more common among individuals who had developed diabetes during the follow-up (33/349) compared with those who had not (9/156); however, the comparison was not statistically significant (odds ratio: 1.86, 95% CI, 0.89-4.28, adjusted for group, age, and sex). CONCLUSION: A higher cumulative HbA1c was significantly associated with a higher risk of retinopathy. No evidence was found for a beneficial effect of a 4-year lifestyle intervention on the long-term occurrence of clinical DR during a median of 22-year follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kaarniranta K, Valtanen M, Keinänen-Kiukaanniemi S, et al. Long-term Cumulative Incidence of Clinically Diagnosed Retinopathy in the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab. 2025. PMID: 38661084. doi:10.1210/clinem/dgae287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。